Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 1.91 USD in weekly data.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 1.88 support.
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The group usually releases upbeat results with huge surprise rates.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 1.91 USD
Weaknesses
  • Low profitability weakens the company.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
OPGEN, INC.105.31%46
-
LONZA GROUP AG64.78%47 531
SEAGEN INC.73.48%34 490
IQVIA HOLDINGS INC.6.17%31 378
CELLTRION, INC.41.16%29 974
MODERNA, INC.262.78%28 000
IMMUNOMEDICS, INC.314.04%20 266
INCYTE CORPORATION0.50%19 193
ALNYLAM PHARMACEUTICALS, IN..22.12%16 310
HANGZHOU TIGERMED CONSULTIN..78.78%14 603
PPD, INC.0.00%12 804
PHARMARON BEIJING CO., LTD.109.12%12 369
QIAGEN N.V.54.70%11 961
CHARLES RIVER LABORATORIES ..52.61%11 582
ICON PUBLIC LIMITED COMPANY18.45%10 736
BIO-TECHNE CORPORATION20.53%10 201
More Results
Financials (USD)
Sales 2020 4,29 M - -
Net income 2020 -24,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,44x
Yield 2020 -
Capitalization 45,7 M 45,7 M -
Capi. / Sales 2020 10,7x
Capi. / Sales 2021 4,12x
Nbr of Employees 39
Free-Float 99,9%
Upcoming event on OPGEN, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating -
Investor Rating -
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability -
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision -
4 months EPS revision
1 year EPS revision -
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes